search
Back to results

Dose-response Effect of Alcohol Ingestion on Steroid Profile (PROFETHYL/2)

Primary Purpose

Alcohol Consumption, Healthy

Status
Completed
Phase
Not Applicable
Locations
Spain
Study Type
Interventional
Intervention
10 g ethanol
20 g ethanol
Water
Sponsored by
Parc de Salut Mar
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Alcohol Consumption focused on measuring Ethanol, Steroid profile, Pharmacokinetics

Eligibility Criteria

18 Years - 55 Years (Adult)FemaleAccepts Healthy Volunteers

Inclusion Criteria:

  • Participants will be healthy women aged 18 to 55 years. Women will enter in studies at the follicular phase of the menstrual cycle, in order to avoid the interference of estrogens.
  • Female subjects (if not postmenopausal) possessing regular menstrual cycle between 26 and 32 days and willing to use effective methods of contraception through the study (sexual abstinence, vasectomized partner, sterilization, intrauterine device, double-barrier method).
  • Clinical history and physical examination demonstrating no organic or psychiatric disorders.
  • The ECG and general blood and urine laboratory tests performed before the study should be within normal ranges. Minor or occasional changes from normal ranges are accepted if, in the investigator's opinion, considering the current state of the art, they are not clinically significant, are not life-threatening for the subjects and do not interfere with the product assessment. These changes and their non-relevance will be justified in writing specifically.
  • The body mass index (BMI=weigh/height2) will range from 18.5 to 29.9 kg/m2, and the weight from 50 to 100 kg.
  • Understanding and accepting the study procedures and signing the informed consent.
  • Agreeing to follow a diet free from ethanol in the 72 hours prior to the start of each session and until the end of the study.
  • Subjects with social or recreational alcohol consumption, at least 3 standard drinks/week and subjects with experience in several drunkenness.

Exclusion Criteria:

  • Not meeting the inclusion criteria.
  • History or clinical evidence of alcoholism, drug abuse, or regular use of psychoactive drugs.
  • Having suffered any organic disease or major surgery in the three months prior to the study start.
  • History of psychiatric disorders.
  • Women presenting amenorrhea or who suffer from moderate to intense premenstrual syndrome. Female subjects using hormonal contraceptive hormones.
  • Smokers of more than 20 cigarettes per day.
  • Taking more than 30 g of alcohol a day
  • Regular use of any drug in the month prior to the study sessions. The treatment with single or limited doses of symptomatic medicinal products in the week prior to the study sessions will not be a reason for exclusion if it is calculated that it has been cleared completely the day of the experimental session.
  • Ingestion of vitamin supplements or antioxidants or nonsteroidal anti-inflammatory drugs in the two weeks preceding the study.
  • Blood donation 8 weeks before or participation in other clinical trials with drugs in the previous 12 weeks.
  • Subjects with intolerance or adverse reactions to ethanol.
  • Subjects who have suffered a hospitalization caused by alcohol intoxication or who have received treatment for drunkenness
  • History or clinical evidence of gastrointestinal, liver, renal or other disorders which may lead to suspecting a disorder in drug absorption, distribution, metabolism or excretion, or that suggest gastrointestinal irritation due to drugs.
  • Subjects unable to understand the nature, consequences of the study and the procedures requested to be followed.
  • Subjects with positive serology to Hepatitis B, C or HIV.
  • Subjects who follow a vegetarian diet.

Sites / Locations

  • Parc Salut Mar

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Experimental

Placebo Comparator

Arm Label

10 g ethanol

20 g ethanol

Water

Arm Description

31 mL of Vodka Absolut® diluted in 369 mL of lemon flavored-water (LFW) Fontvella®. A total volume of 400 mL of the drink will be administered, distributed in three 133 mL cool glasses. Administration of ethanol beverage will be controlled: participants will have 5 minutes to drink each glass.

63 mL of Vodka Absolut® diluted in 337 mL of lemon flavored-water (LFW) Fontvella®. A total volume of 400 mL of the drink will be administered, distributed in three 133 mL cool glasses. Administration of ethanol beverage will be controlled: participants will have 5 minutes to drink each glass.

400 mL of lemon flavored-water Fontvella®. A total volume of 400 mL of the drink will be administered, distributed in three 133 mL cool glasses. The administration will be controlled: participants will have 5 minutes to drink each glass.

Outcomes

Primary Outcome Measures

Change from baseline steroid profile
24 hours urine will be collected before each experimental session and also up to 24 hours after administration.
Change from baseline Ethyl glucuronide concentrations
Ethyl glucuronide in urine will be measured by Liquid chromatography-mass spectrometry (LC-MS) using deuterated analogs as Internal Standards.
Change from baseline Urine Ethyl sulfate concentrations
Ethyl sulfate in urine will be measured by Liquid chromatography-mass spectrometry (LC-MS) using deuterated analogs as Internal Standards.

Secondary Outcome Measures

Change from baseline alcohol breath air concentrations
Alcohol concentration in breath air will be determined baseline (pre-administration) and up to 6 hours post-administration.
Urine Creatinine concentrations
Creatinine will be determined in each urine sample
Change from baseline subjective effects of ethanol
Participants will self-report their experience on a Visual Analogical Scale (VAS): before administration and till 6h post-administration
Number of Participants with Serious and Non-Serious Adverse Events
Collection of adverse effects spontaneously by the participants and/or observed by the investigators.
Change from baseline heart rate
Monitoring heart rate before administration and till 6h post-administration.
Change from baseline oral temperature
Monitoring oral temperature before administration and till 6h post-administration.
Change from baseline blood pressure
Monitoring blood pressure before administration and till 6h post-administration.
Urine pH
pH will be determined in each urine sample
Urine specific gravity
Specific gravity will be determined in each urine sample
Uridine diphosphoglucuronosyltransferase family 2 member B17 (UGT2B17) deletion genotype
A blood sample for genotyping will be collected. The buffy coat will be stored a -20 degrees celsius (ºC). If deemed necessary for the interpretation of results, DNA will be extracted and evaluated following quantitative multiplex amplification polymerase chain reaction (PCR) for the evaluation of UGT2B17 deletion and copy number variation (CNVs)

Full Information

First Posted
July 28, 2016
Last Updated
October 4, 2017
Sponsor
Parc de Salut Mar
Collaborators
World Anti-doping Agency
search

1. Study Identification

Unique Protocol Identification Number
NCT02869763
Brief Title
Dose-response Effect of Alcohol Ingestion on Steroid Profile
Acronym
PROFETHYL/2
Official Title
Dose-response Effect of Alcohol Ingestion on Steroid Profile: Gender and Ethnic Aspects
Study Type
Interventional

2. Study Status

Record Verification Date
October 2017
Overall Recruitment Status
Completed
Study Start Date
May 2016 (Actual)
Primary Completion Date
November 2016 (Actual)
Study Completion Date
September 2017 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Parc de Salut Mar
Collaborators
World Anti-doping Agency

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The aim of the clinical trial is to study the intra-individual variation of steroid profile parameters after experimental administration of different doses of ethanol in Caucasian women.
Detailed Description
The introduction of the so called 'endocrine module' of the athlete's biological passport needs to consider the numerous reports showing the effect of ethanol ingestion on the steroid profile. A steroid profile would only be useful for longitudinal monitoring and statistical evaluation if it has not been altered by any uncontrolled circumstance, very particularly alcohol consumption. There is an urgent need to study the perpetuation that alcohol ingestion causes to the individual steroid profile and if possible establish cut-off values for markers of ethanol ingestion granting that the steroid profile determined has not been affected by such ingestion. Subjects will be genotyped for genetic deletion polymorphism in the uridine diphosphoglucuronosyltransferase family 2 member B17 gene (UGT2B17) related to testosterone glucuronidation regulation. The objective of the clinical trial is to study the intra-individual variation of steroid profile parameters as a result of the ingestion of different doses of ethanol in Caucasian women (complementing previous studies performed in men).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Alcohol Consumption, Healthy
Keywords
Ethanol, Steroid profile, Pharmacokinetics

7. Study Design

Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
12 (Actual)

8. Arms, Groups, and Interventions

Arm Title
10 g ethanol
Arm Type
Experimental
Arm Description
31 mL of Vodka Absolut® diluted in 369 mL of lemon flavored-water (LFW) Fontvella®. A total volume of 400 mL of the drink will be administered, distributed in three 133 mL cool glasses. Administration of ethanol beverage will be controlled: participants will have 5 minutes to drink each glass.
Arm Title
20 g ethanol
Arm Type
Experimental
Arm Description
63 mL of Vodka Absolut® diluted in 337 mL of lemon flavored-water (LFW) Fontvella®. A total volume of 400 mL of the drink will be administered, distributed in three 133 mL cool glasses. Administration of ethanol beverage will be controlled: participants will have 5 minutes to drink each glass.
Arm Title
Water
Arm Type
Placebo Comparator
Arm Description
400 mL of lemon flavored-water Fontvella®. A total volume of 400 mL of the drink will be administered, distributed in three 133 mL cool glasses. The administration will be controlled: participants will have 5 minutes to drink each glass.
Intervention Type
Dietary Supplement
Intervention Name(s)
10 g ethanol
Other Intervention Name(s)
Vodka Absolut®
Intervention Description
31 mL of Vodka Absolut® diluted in 369 mL of lemon flavored-water (LFW) Fontvella®. A total volume of 400 mL of the drink will be administered, distributed in three 133 mL cool glasses. Administration of ethanol beverage will be controlled: participants will have 5 minutes to drink each glass.
Intervention Type
Dietary Supplement
Intervention Name(s)
20 g ethanol
Other Intervention Name(s)
Vodka Absolut®
Intervention Description
63 mL of Vodka Absolut® diluted in 337 mL of lemon flavored-water (LFW) Fontvella®. A total volume of 400 mL of the drink will be administered, distributed in three 133 mL cool glasses. Administration of ethanol beverage will be controlled: participants will have 5 minutes to drink each glass.
Intervention Type
Dietary Supplement
Intervention Name(s)
Water
Other Intervention Name(s)
Lemon flavored-water Fontvella®
Intervention Description
400 mL of lemon flavored-water Fontvella®. A total volume of 400 mL of the drink will be administered, distributed in three 133 mL cool glasses. The administration will be controlled: participants will have 5 minutes to drink each glass.
Primary Outcome Measure Information:
Title
Change from baseline steroid profile
Description
24 hours urine will be collected before each experimental session and also up to 24 hours after administration.
Time Frame
From one day before administration till 24 hours after administration
Title
Change from baseline Ethyl glucuronide concentrations
Description
Ethyl glucuronide in urine will be measured by Liquid chromatography-mass spectrometry (LC-MS) using deuterated analogs as Internal Standards.
Time Frame
From baseline till 24 hours after administration
Title
Change from baseline Urine Ethyl sulfate concentrations
Description
Ethyl sulfate in urine will be measured by Liquid chromatography-mass spectrometry (LC-MS) using deuterated analogs as Internal Standards.
Time Frame
From baseline till 24 hours after administration
Secondary Outcome Measure Information:
Title
Change from baseline alcohol breath air concentrations
Description
Alcohol concentration in breath air will be determined baseline (pre-administration) and up to 6 hours post-administration.
Time Frame
From baseline till 6 hours after administration
Title
Urine Creatinine concentrations
Description
Creatinine will be determined in each urine sample
Time Frame
From one day before administration till 24 hours after administration
Title
Change from baseline subjective effects of ethanol
Description
Participants will self-report their experience on a Visual Analogical Scale (VAS): before administration and till 6h post-administration
Time Frame
From baseline till 6 hours after administration
Title
Number of Participants with Serious and Non-Serious Adverse Events
Description
Collection of adverse effects spontaneously by the participants and/or observed by the investigators.
Time Frame
Through study completion, an average of 1 year
Title
Change from baseline heart rate
Description
Monitoring heart rate before administration and till 6h post-administration.
Time Frame
From baseline to 6 hours after administration
Title
Change from baseline oral temperature
Description
Monitoring oral temperature before administration and till 6h post-administration.
Time Frame
From baseline to 6 hours after administration
Title
Change from baseline blood pressure
Description
Monitoring blood pressure before administration and till 6h post-administration.
Time Frame
From baseline to 6 hours after administration
Title
Urine pH
Description
pH will be determined in each urine sample
Time Frame
From one day before administration till 24 hours after administration
Title
Urine specific gravity
Description
Specific gravity will be determined in each urine sample
Time Frame
From one day before administration till 24 hours after administration
Title
Uridine diphosphoglucuronosyltransferase family 2 member B17 (UGT2B17) deletion genotype
Description
A blood sample for genotyping will be collected. The buffy coat will be stored a -20 degrees celsius (ºC). If deemed necessary for the interpretation of results, DNA will be extracted and evaluated following quantitative multiplex amplification polymerase chain reaction (PCR) for the evaluation of UGT2B17 deletion and copy number variation (CNVs)
Time Frame
Baseline

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
55 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Participants will be healthy women aged 18 to 55 years. Women will enter in studies at the follicular phase of the menstrual cycle, in order to avoid the interference of estrogens. Female subjects (if not postmenopausal) possessing regular menstrual cycle between 26 and 32 days and willing to use effective methods of contraception through the study (sexual abstinence, vasectomized partner, sterilization, intrauterine device, double-barrier method). Clinical history and physical examination demonstrating no organic or psychiatric disorders. The ECG and general blood and urine laboratory tests performed before the study should be within normal ranges. Minor or occasional changes from normal ranges are accepted if, in the investigator's opinion, considering the current state of the art, they are not clinically significant, are not life-threatening for the subjects and do not interfere with the product assessment. These changes and their non-relevance will be justified in writing specifically. The body mass index (BMI=weigh/height2) will range from 18.5 to 29.9 kg/m2, and the weight from 50 to 100 kg. Understanding and accepting the study procedures and signing the informed consent. Agreeing to follow a diet free from ethanol in the 72 hours prior to the start of each session and until the end of the study. Subjects with social or recreational alcohol consumption, at least 3 standard drinks/week and subjects with experience in several drunkenness. Exclusion Criteria: Not meeting the inclusion criteria. History or clinical evidence of alcoholism, drug abuse, or regular use of psychoactive drugs. Having suffered any organic disease or major surgery in the three months prior to the study start. History of psychiatric disorders. Women presenting amenorrhea or who suffer from moderate to intense premenstrual syndrome. Female subjects using hormonal contraceptive hormones. Smokers of more than 20 cigarettes per day. Taking more than 30 g of alcohol a day Regular use of any drug in the month prior to the study sessions. The treatment with single or limited doses of symptomatic medicinal products in the week prior to the study sessions will not be a reason for exclusion if it is calculated that it has been cleared completely the day of the experimental session. Ingestion of vitamin supplements or antioxidants or nonsteroidal anti-inflammatory drugs in the two weeks preceding the study. Blood donation 8 weeks before or participation in other clinical trials with drugs in the previous 12 weeks. Subjects with intolerance or adverse reactions to ethanol. Subjects who have suffered a hospitalization caused by alcohol intoxication or who have received treatment for drunkenness History or clinical evidence of gastrointestinal, liver, renal or other disorders which may lead to suspecting a disorder in drug absorption, distribution, metabolism or excretion, or that suggest gastrointestinal irritation due to drugs. Subjects unable to understand the nature, consequences of the study and the procedures requested to be followed. Subjects with positive serology to Hepatitis B, C or HIV. Subjects who follow a vegetarian diet.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Rafael de la Torre, PhD
Organizational Affiliation
IMIM-Hospital del Mar Medical Research Institute
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
José Antonio Pascual, PhD
Organizational Affiliation
IMIM-Hospital del Mar Medical Research Institute
Official's Role
Study Chair
Facility Information:
Facility Name
Parc Salut Mar
City
Barcelona
ZIP/Postal Code
08003
Country
Spain

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
22852062
Citation
Arranz S, Chiva-Blanch G, Valderas-Martinez P, Medina-Remon A, Lamuela-Raventos RM, Estruch R. Wine, beer, alcohol and polyphenols on cardiovascular disease and cancer. Nutrients. 2012 Jul;4(7):759-781. doi: 10.3390/nu4070759. Epub 2012 Jul 10.
Results Reference
result
PubMed Identifier
18559444
Citation
Bagnardi V, Zatonski W, Scotti L, La Vecchia C, Corrao G. Does drinking pattern modify the effect of alcohol on the risk of coronary heart disease? Evidence from a meta-analysis. J Epidemiol Community Health. 2008 Jul;62(7):615-9. doi: 10.1136/jech.2007.065607.
Results Reference
result
PubMed Identifier
21616946
Citation
Dahl H, Hammarberg A, Franck J, Helander A. Urinary ethyl glucuronide and ethyl sulfate testing for recent drinking in alcohol-dependent outpatients treated with acamprosate or placebo. Alcohol Alcohol. 2011 Sep-Oct;46(5):553-7. doi: 10.1093/alcalc/agr055. Epub 2011 May 26.
Results Reference
result
PubMed Identifier
12054359
Citation
Dahl H, Stephanson N, Beck O, Helander A. Comparison of urinary excretion characteristics of ethanol and ethyl glucuronide. J Anal Toxicol. 2002 May-Jun;26(4):201-4. doi: 10.1093/jat/26.4.201.
Results Reference
result
PubMed Identifier
24773137
Citation
Jatlow PI, Agro A, Wu R, Nadim H, Toll BA, Ralevski E, Nogueira C, Shi J, Dziura JD, Petrakis IL, O'Malley SS. Ethyl glucuronide and ethyl sulfate assays in clinical trials, interpretation, and limitations: results of a dose ranging alcohol challenge study and 2 clinical trials. Alcohol Clin Exp Res. 2014 Jul;38(7):2056-65. doi: 10.1111/acer.12407. Epub 2014 Apr 28.
Results Reference
result
PubMed Identifier
17159008
Citation
Di Castelnuovo A, Costanzo S, Bagnardi V, Donati MB, Iacoviello L, de Gaetano G. Alcohol dosing and total mortality in men and women: an updated meta-analysis of 34 prospective studies. Arch Intern Med. 2006 Dec 11-25;166(22):2437-45. doi: 10.1001/archinte.166.22.2437.
Results Reference
result
PubMed Identifier
3390919
Citation
Falk O, Palonek E, Bjorkhem I. Effect of ethanol on the ratio between testosterone and epitestosterone in urine. Clin Chem. 1988 Jul;34(7):1462-4.
Results Reference
result
PubMed Identifier
22111604
Citation
Gaedigk A, Twist GP, Leeder JS. CYP2D6, SULT1A1 and UGT2B17 copy number variation: quantitative detection by multiplex PCR. Pharmacogenomics. 2012 Jan;13(1):91-111. doi: 10.2217/pgs.11.135. Epub 2011 Nov 23.
Results Reference
result
PubMed Identifier
20355168
Citation
Grosse J, Anielski P, Sachs H, Thieme D. Ethylglucuronide as a potential marker for alcohol-induced elevation of urinary testosterone/epitestosterone ratios. Drug Test Anal. 2009 Nov;1(11-12):526-30. doi: 10.1002/dta.110.
Results Reference
result
PubMed Identifier
17558515
Citation
Halter CC, Dresen S, Auwaerter V, Wurst FM, Weinmann W. Kinetics in serum and urinary excretion of ethyl sulfate and ethyl glucuronide after medium dose ethanol intake. Int J Legal Med. 2008 Mar;122(2):123-8. doi: 10.1007/s00414-007-0180-8. Epub 2007 Jun 9.
Results Reference
result
PubMed Identifier
16332934
Citation
Jakobsson J, Ekstrom L, Inotsume N, Garle M, Lorentzon M, Ohlsson C, Roh HK, Carlstrom K, Rane A. Large differences in testosterone excretion in Korean and Swedish men are strongly associated with a UDP-glucuronosyl transferase 2B17 polymorphism. J Clin Endocrinol Metab. 2006 Feb;91(2):687-93. doi: 10.1210/jc.2005-1643. Epub 2005 Dec 6.
Results Reference
result
PubMed Identifier
16785338
Citation
American Heart Association Nutrition Committee; Lichtenstein AH, Appel LJ, Brands M, Carnethon M, Daniels S, Franch HA, Franklin B, Kris-Etherton P, Harris WS, Howard B, Karanja N, Lefevre M, Rudel L, Sacks F, Van Horn L, Winston M, Wylie-Rosett J. Diet and lifestyle recommendations revision 2006: a scientific statement from the American Heart Association Nutrition Committee. Circulation. 2006 Jul 4;114(1):82-96. doi: 10.1161/CIRCULATIONAHA.106.176158. Epub 2006 Jun 19. Erratum In: Circulation. 2006 Dec 5;114(23):e629. Circulation. 2006 Jul 4;114(1):e27.
Results Reference
result
PubMed Identifier
16933054
Citation
Rinaldi S, Peeters PH, Bezemer ID, Dossus L, Biessy C, Sacerdote C, Berrino F, Panico S, Palli D, Tumino R, Khaw KT, Bingham S, Allen NE, Key T, Jensen MK, Overvad K, Olsen A, Tjonneland A, Amiano P, Ardanaz E, Agudo A, Martinez-Garcia C, Quiros JR, Tormo MJ, Nagel G, Linseisen J, Boeing H, Schulz M, Grobbee DE, Bueno-de-Mesquita HB, Koliva M, Kyriazi G, Thrichopoulou A, Boutron-Ruault MC, Clavel-Chapelon F, Ferrari P, Slimani N, Saracci R, Riboli E, Kaaks R. Relationship of alcohol intake and sex steroid concentrations in blood in pre- and post-menopausal women: the European Prospective Investigation into Cancer and Nutrition. Cancer Causes Control. 2006 Oct;17(8):1033-43. doi: 10.1007/s10552-006-0041-7.
Results Reference
result
PubMed Identifier
9626146
Citation
Santner SJ, Albertson B, Zhang GY, Zhang GH, Santulli M, Wang C, Demers LM, Shackleton C, Santen RJ. Comparative rates of androgen production and metabolism in Caucasian and Chinese subjects. J Clin Endocrinol Metab. 1998 Jun;83(6):2104-9. doi: 10.1210/jcem.83.6.4898.
Results Reference
result
PubMed Identifier
21895709
Citation
Snell LD, Ramchandani VA, Saba L, Herion D, Heilig M, George DT, Pridzun L, Helander A, Schwandt ML, Phillips MJ, Hoffman PL, Tabakoff B; WHO/ISBRA Study on State and Trait Markers of Alcohol Use and Dependence Investigators. The biometric measurement of alcohol consumption. Alcohol Clin Exp Res. 2012 Feb;36(2):332-41. doi: 10.1111/j.1530-0277.2011.01605.x. Epub 2011 Sep 6.
Results Reference
result
PubMed Identifier
20122450
Citation
Sottas PE, Saugy M, Saudan C. Endogenous steroid profiling in the athlete biological passport. Endocrinol Metab Clin North Am. 2010 Mar;39(1):59-73, viii-ix. doi: 10.1016/j.ecl.2009.11.003.
Results Reference
result
PubMed Identifier
18927247
Citation
Starcevic B, Butch AW. Genetic variations in UDP-glucuronosyl transferase 2B17: implications for testosterone excretion profiling and doping control programs. Clin Chem. 2008 Dec;54(12):1945-7. doi: 10.1373/clinchem.2008.110106. Epub 2008 Oct 16. No abstract available.
Results Reference
result
PubMed Identifier
19282302
Citation
Strahm E, Sottas PE, Schweizer C, Saugy M, Dvorak J, Saudan C. Steroid profiles of professional soccer players: an international comparative study. Br J Sports Med. 2009 Dec;43(14):1126-30. doi: 10.1136/bjsm.2008.056242. Epub 2009 Mar 12.
Results Reference
result
PubMed Identifier
22213685
Citation
Thieme D, Grosse J, Keller L, Graw M. Urinary concentrations of ethyl glucuronide and ethyl sulfate as thresholds to determine potential ethanol-induced alteration of steroid profiles. Drug Test Anal. 2011 Nov-Dec;3(11-12):851-6. doi: 10.1002/dta.396.
Results Reference
result
PubMed Identifier
24254402
Citation
Xu L, Au Yeung SL, Kavikondala S, Leung GM, Schooling CM. Testosterone concentrations in young healthy US versus Chinese men. Am J Hum Biol. 2014 Jan-Feb;26(1):99-102. doi: 10.1002/ajhb.22482. Epub 2013 Nov 19.
Results Reference
result

Learn more about this trial

Dose-response Effect of Alcohol Ingestion on Steroid Profile

We'll reach out to this number within 24 hrs